Ticker > Company >

Sun Pharma Adv. Res share price

Sun Pharma Advanced Research Company Ltd.

NSE: SPARC BSE: 532872 SECTOR: Business Support  129k   220   24

165.90
0 0
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 167.2

Today's Low

₹ 162.95

52 Week High

₹ 257.7

52 Week Low

₹ 109.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

5383.81 Cr.

Enterprise Value

5275.75 Cr.

No. of Shares

32.45 Cr.

P/E

0

P/B

0

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  -6.79

CASH

155.06 Cr.

DEBT

47 Cr.

Promoter Holding

65.67 %

EPS (TTM)

₹  -10.64

Sales Growth

-68.36%

ROE

-121.73 %

ROCE

-112.88%

Profit Growth

-74.36 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-68.36%
3 Year-33.16%
5 Year-16.21%

Profit Growth

1 Year-74.36%
3 Year-182.81%
5 Year-192.27%

ROE%

1 Year-121.73%
3 Year-88.49%
5 Year-98.11%

ROCE %

1 Year-112.88%
3 Year-135.97%
5 Year-168.19%

Debt/Equity

0.3764

Price to Cash Flow

-12.54

Interest Cover Ratio

-233.4763

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 65.67 0.00
Dec 2024 65.67 0.00
Sep 2024 65.67 2.78
Jun 2024 65.67 2.78
Mar 2024 65.67 2.78
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has a high promoter holding of 65.67%.

 Limitations

  • The company has shown a poor profit growth of -182.810168104835% for the Past 3 years.
  • The company has shown a poor revenue growth of -33.1571013347336% for the Past 3 years.
  • Company has a poor ROE of -88.4851666666667% over the past 3 years.
  • Company has a poor ROCE of -135.967133333333% over the past 3 years
  • Company has low Interest coverage ratio of -233.4763.
  • Company has contingent liabilities of 83.5684 Cr.
  • Company has negative cash flow from operations of -429.4265.
  • The company has a low EBITDA margin of -243.43168% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 16.56 16.81 12.86 14.91 27.19
Total Expenditure 124.08 111.93 116.71 89.29 81.11
Operating Profit -107.52 -95.12 -103.85 -74.38 -53.92
Other Income 4.4 1.56 0.04 0.19 0
Interest 0.88 0.52 1.11 2.77 4.51
Depreciation 2.69 2.76 2.77 2.75 2.55
Exceptional Items 0 0 0 0 0
Profit Before Tax -106.69 -96.84 -107.69 -79.71 -60.98
Tax 0 0 0 0 0
Profit After Tax -106.69 -96.84 -107.69 -79.71 -60.98
Adjusted EPS (Rs) -3.29 -2.98 -3.32 -2.46 -1.88

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 76.81 252.96 137.25 238.78 75.55
Total Expenditure 386.83 387.93 324 452.84 479.34
Operating Profit -310.01 -134.98 -186.75 -214.06 -403.79
Other Income 9.76 5.41 6.84 10.88 29.47
Interest 2.67 10.65 13.33 7.63 1.66
Depreciation 9.48 10.92 10.16 11.77 12.13
Exceptional Items 0 0 0 0 0
Profit Before Tax -312.4 -151.14 -203.4 -222.58 -388.11
Tax 0 0 0 0 0
Net Profit -312.4 -151.14 -203.4 -222.58 -388.11
Adjusted EPS (Rs.) -11.92 -5.77 -7.48 -6.86 -11.96

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 26.21 26.21 27.19 32.45 32.45
Total Reserves -44.84 -194.46 4.04 480.32 92.4
Borrowings 6.38 112.5 0 0 0
Other N/C liabilities 49.47 52.09 77.43 138.41 117.59
Current liabilities 235.36 233.35 171.43 178.95 243.89
Total Liabilities 272.56 229.69 280.08 830.13 486.33
Assets
Net Block 103.86 90.56 91.87 105.75 102.65
Capital WIP 3.57 5.23 3.72 1.87 1.27
Intangible WIP 28.49 0 22.65 25.13 42.53
Investments 0 0 0 0 0.42
Loans & Advances 69.24 70.64 67.83 64.8 67.67
Other N/C Assets 0.2 3.46 22.87 177.61 25.4
Current Assets 67.19 59.8 71.15 454.96 246.41
Total Assets 272.56 229.69 280.08 830.13 486.33
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -312.4 -151.14 -203.4 -222.58 -388.11
Adjustment 9.44 48.75 16.67 6.99 -11.33
Changes in Assets & Liabilities 102.02 -47.88 -26.05 141.11 -25.88
Tax Paid -9.86 -1.63 4.54 5.37 -4.11
Operating Cash Flow -210.81 -151.9 -208.23 -69.12 -429.43
Investing Cash Flow 155.35 1.56 -29.17 -548.28 391.11
Financing Cash Flow 55.46 159.28 229.32 616.76 42.8
Net Cash Flow 0 8.95 -8.08 -0.64 4.48

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 65.67 65.67 65.67 65.67 65.67
aalok dilip shanghvi 0.11 0.11 0.11 0.11 0.11
aditya medisales limited 1.51 1.51 1.51 1.51 1.51
dilip.s.shanghvi - - - - 19.05
kumud shantilal shanghvi - - - - 0.01
raksha sudhir valia - - - - 1.28
shanghvi family & friends... - - - - 0.05
shanghvi finance private ... - - - - 42.28
sudhir vrundavandas valia... - - - - 0.57
unimed investments limite... 0.39 0.39 0.39 0.39 0.39
vibha dilip shanghvi 0.33 0.33 0.33 0.33 0.33
vidhi dilip shanghvi 0.11 0.11 0.11 0.11 0.11
dilip shantilal shanghvi 19.05 19.05 19.05 19.05 -
kumud s. shanghvi 0.01 0.01 0.01 0.01 -
raksha s.valia 1.28 1.28 1.28 1.28 -
shanghvi family & friends... 0.05 0.05 0.05 0.05 -
shanghvi finance private ... 42.28 42.28 42.28 42.28 -
sudhir valia 0.57 0.57 0.57 0.57 -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 34.33 34.33 34.33 34.33 34.33
enam holdings pvt ltd - - - - 1.04
lakshdeep investments & f... 1.58 1.86 1.86 1.86 1.86
llp - - - - 0.29
paresh mohanlal parekh 1.12 1.12 1.12 1.12 1.12
sun pharmaceutical indust... 3.18 3.18 3.18 3.18 3.18
vijay mohanlal parekh 1.13 1.13 1.13 1.13 1.13
enam securities private l... 1.04 1.04 1.04 1.04 -
rekha jhunjhunwala - - - 1.59 -
jhunjhunwala rekha rakesh... 1.94 1.94 1.94 - -

Annual Reports

Title Action
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit ACUITE RATINGS
TYPE AGENCY ACTION
Research BOB Capital Market

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q3FY22
Concall Q2FY25
Concall Q2FY24
Concall Q2FY21
Concall Q2FY20
TYPE QUARTER ACTION
Presentation Q2FY25
Presentation Q2FY22
Presentation Q1FY21
Presentation Q1FY20
Presentation H1FY21

Company News

Sun Pharma Adv. Res Stock Price Analysis and Quick Research Report. Is Sun Pharma Adv. Res an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Sun Pharma Adv. Res stock price today is Rs 165.9. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sun Pharma Adv. Res . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sun Pharma Adv. Res has a PE ratio of -15.5953298614375 which is low and comparatively undervalued .

  • Share Price: - The current share price of Sun Pharma Adv. Res is Rs 165.9. One can use valuation calculators of ticker to know if Sun Pharma Adv. Res share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sun Pharma Adv. Res has ROA of -58.962 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sun Pharma Adv. Res has a Current ratio of 1.0103 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sun Pharma Adv. Res has a ROE of -121.7332 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Sun Pharma Adv. Res has a Debt to Equity ratio of 0.3764 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Sun Pharma Adv. Res has reported revenue growth of -68.362 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Sun Pharma Adv. Res for the current financial year is -534.502742063371 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sun Pharma Adv. Res is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sun Pharma Adv. Res is Rs -10.6378 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sun Pharma Adv. Res in Ticker for free. Also, one can get the intrinsic value of Sun Pharma Adv. Res by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Sun Pharma Adv. Res
X